Mitigating the impacts of COVID-19: where are the mental health trials?
Lancet Psychiatry
.
2021 Aug;8(8):647-650.
doi: 10.1016/S2215-0366(21)00204-2.
Epub 2021 Jun 1.
Authors
Simon Gilbody
1
,
Elizabeth Littlewood
2
,
Samantha Gascoyne
2
,
Dean McMillan
3
,
David Ekers
4
,
Carolyn A Chew-Graham
5
,
Cathy Creswell
6
,
John Wright
7
Affiliations
1
University of York, York YO10 5DD, UK. Electronic address: simon.gilbody@york.ac.uk.
2
University of York, York YO10 5DD, UK.
3
University of York, York YO10 5DD, UK; Hull York Medical School, York, UK.
4
University of York, York YO10 5DD, UK; Research and Development, Tees, Esk and Wear Valleys NHS Foundation Trust, Middlesbrough, UK.
5
School of Medicine, Keele University, Staffordshire, UK.
6
University of Oxford, Oxford, UK.
7
Yorkshire and Humberside Applied Research Collaboration, Bradford Institute for Health Research, Bradford, UK.
PMID:
34087112
PMCID:
PMC8169044
DOI:
10.1016/S2215-0366(21)00204-2
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
COVID-19*
Depression
Humans
Mental Disorders* / therapy
Mental Health
SARS-CoV-2
Grants and funding
MR/V028510/1/MRC_/Medical Research Council/United Kingdom